Key result
Serum apolipoprotein A1 was identified as an independent predictor of COVID-19 severity (adjusted OR 0.865; 95% CI 0.800-0.935; p<0.001).
Why the study?
Dyslipidemia has been observed in patients with COVID-19, but the predictive value of blood lipid profiles for disease severity needed further investigation.
Does serum apolipoprotein A1 level predict the severity of COVID-19?
Observational (n=219)
No
Does serum apolipoprotein A1 level predict the severity of COVID-19?
Odds Ratio: 0.865 (95% CI 0.8–0.935)
p-value: p=<0.001
Low serum levels of apolipoprotein A1 are independently associated with increased severity of COVID-19.
ApoA1 may aid COVID-19 severity stratification; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: Dyslipidemia has been observed in patients with coronavirus disease 2019 (COVID-19). This study aimed to investigate blood lipid profiles in patients with COVID-19 and to explore their predictive values for COVID-19 severity. METHODS: A total of 142 consecutive patients with COVID-19 were included in this single-center retrospective study. Blood lipid profile characteristics were investigated in patients with COVID-19 in comparison with 77 age- and gender-matched healthy subjects, their predictive values for COVID-19 severity were analyzed by using multivariable logistic regression analysis, and their prediction efficiencies were evaluated by using receiver operator characteristic (ROC) curves. RESULTS: There were 125 and 17 cases in the non-severe and severe groups, respectively. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A1 (ApoA1) gradually decreased across the groups in the following order: healthy controls, non-severe group, and severe group. ApoA1 was identified as an independent risk factor for COVID-19 severity (adjusted odds ratio [OR]: 0.865, 95% confidence interval [CI]: 0.800-0.935, p < 0.001), along with interleukin-6 (IL-6) (adjusted OR: 1.097, 95% CI: 1.034-1.165, p = 0.002). ApoA1 exhibited the highest area under the ROC curve (AUC) among all single markers (AUC: 0.896, 95% CI: 0.834-0.941); moreover, the risk model established using ApoA1 and IL-6 enhanced prediction efficiency (AUC: 0.977, 95% CI: 0.932-0.995). CONCLUSION: Blood lipid profiles in patients with COVID-19 are quite abnormal compared with those in healthy subjects, especially in severe cases. Serum ApoA1 may represent a good indicator for predicting the severity of COVID-19.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2021) conducted an observational in COVID-19 (n=219). Serum apolipoprotein A1 (ApoA1) was evaluated on COVID-19 severity (adjusted OR 0.865, 95% CI 0.800-0.935, p=<0.001). Serum apolipoprotein A1 was identified as an independent predictor of COVID-19 severity (adjusted OR 0.865; 95% CI 0.800-0.935; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: